A Record-Breaking Outbreak With an Uncertain True Scale
The Democratic Republic of Congo is now at the center of the largest outbreak of Bundibugyo Ebola virus ever recorded in history. As of July 14, 2026, the DRC government reported 2,011 confirmed cases and 754 deaths, with 753 patients currently hospitalized in isolation, according to data from the European Centre for Disease Prevention and Control. The outbreak, declared a Public Health Emergency of International Concern by the WHO on May 16, 2026, has now killed more people in ten weeks than the entire 2007 Bundibugyo outbreak that gave this viral species its name.
WHO Director-General Tedros Adhanom Ghebreyesus warned this week that the pace of the current outbreak has no modern precedent for this strain: the 2018–2019 Zaire Ebola outbreak in the DRC took more than 10 months to reach 2,000 confirmed cases. The current Bundibugyo outbreak has done so in under two months.
And health officials caution that 2,011 confirmed cases may be a significant undercount.
Why This Matters to U.S. Readers
This outbreak is not occurring in isolation from the United States. On July 10, the CDC confirmed that a U.S. citizen working for a humanitarian organization in the DRC had tested positive for Bundibugyo virus and was medically evacuated to Germany on July 13. No cases have been confirmed in the United States from this outbreak — but the U.S. is actively monitoring incoming travelers.
The CDC implemented entry restrictions covering travelers from the DRC, Uganda, and South Sudan. The most recent 30-day entry restriction order, issued June 21, 2026, is set to expire around July 21 — in four days. Whether federal authorities extend those restrictions will be one of the most watched global health policy decisions of the coming week.
Additionally, France confirmed a case in a physician who returned from the DRC on a humanitarian mission, underscoring that international spread through healthcare and aid workers is already occurring.
What We Know So Far
The outbreak was declared on May 15, 2026, after cases were confirmed in Ituri province in eastern DRC. It has since spread to five provinces, including Haut-Uele and Tshopo — both formally added to the epidemic zone as recently as July 11.
As of July 14, Ituri province remained the most heavily affected area, accounting for 1,808 confirmed cases and 631 deaths. The outbreak is being driven by ongoing undetected community transmission. WHO confirmed that more than 80% of newly confirmed patients were not already identified contacts of known cases — a sign that surveillance is not keeping pace with the spread.
A WHO official who spoke after visiting the region, Chikwe Ihekweazu, Executive Director of the WHO Health Emergencies Programme, warned that the true number of cases may be at least double the official count — a figure echoed by earlier estimates from WHO Representative to the DRC Dr. Anne Ancia, who placed the range at two to four times official figures.
Doctors Without Borders (MSF) warned Wednesday that"in less than five weeks, the number of confirmed cases has tripled" while "the number of deaths has increased more than fivefold," calling for an urgent scaling up of the international medical response.
Where the Risk Is Highest
Within the DRC, active epidemic zones now include Ituri, North Kivu, Haut-Uele, Tshopo, and additional affected provinces, with Ituri accounting for the overwhelming majority of confirmed deaths. In Uganda, 20 confirmed cases and two deaths have been reported, with no new cases identified since June 30, though the country shares a porous border with DRC's most affected regions.
For U.S. travelers and aid workers, the risk profile is concentrated among people who:
- Are currently in or planning to travel to eastern DRC, particularly Ituri and North Kivu provinces
- Work for humanitarian organizations with personnel on the ground in affected areas
- Are transiting through Uganda or neighboring countries with ongoing case monitoring
For the general U.S. public with no travel to affected regions, the direct risk remains very low. However, the public health community is watching closely for evidence of additional imported cases in countries with significant travel links to the region.
What the Evidence Shows and What It Does Not
There is currently no approved vaccine for the Bundibugyo strain of Ebola virus. This is a critical distinction from prior DRC outbreaks. The two licensed Ebola vaccines — Ervebo and the Mvabea/Zabdeno regimen — both target the Zaire strain and are not considered effective against Bundibugyo. The WHO has recommended against their use in this outbreak.
A clinical trial evaluating two experimental therapies — the monoclonal antibody MBP134 and the antiviral remdesivir — began in DRC on July 2, 2026, with more than 1,200 treatment doses available. Treatment remains entirely supportive for most patients while trial results are pending.
The Bundibugyo virus is estimated to carry a case fatality rate of approximately 25% to 50% in prior outbreaks. Whether the current outbreak's mortality rate differs — potentially reflecting improved supportive care, earlier detection, or the geographic and demographic characteristics of affected populations — is still under analysis.
Who Faces the Greatest Risk?
Based on current outbreak data and WHO guidance, the people facing the highest risk include:
- Residents of affected provinces in eastern DRC, particularly those without consistent access to isolation facilities or supportive care
- Health care workers and humanitarian aid personnel in the epidemic zone
- Household contacts of confirmed cases, who make up a significant share of transmission chains
- People traveling through border areas between DRC and Uganda
- Travelers returning from DRC, Uganda, or South Sudan to countries with limited Ebola screening protocols
For U.S. travelers with essential travel planned to the affected region, the State Department has issued travel advisories, and travelers should check current advisories at travel.state.gov before departing.
Symptoms and Warning Signs to Watch For
Bundibugyo virus disease typically presents with:
- Sudden onset of fever and severe headache
- Muscle pain and fatigue
- Vomiting, diarrhea, and stomach pain
- Unexplained bleeding or bruising (in more severe cases)
- Rash
Symptoms usually appear between two and 21 days after exposure. Anyone who has traveled to an affected area in the past three weeks and develops any of these symptoms should contact their health care provider immediately, inform them of the travel history before visiting a clinic, and call ahead rather than arriving at an emergency room unannounced.
What You Can Do Now
- If you have recently returned from the DRC, Uganda, or South Sudan, monitor your health closely for 21 days and report any fever or symptoms to a health care provider immediately, noting your travel history.
- Check the CDC Ebola travel notices for the latest traveler health guidance, including any active entry requirements or screening protocols.
- Humanitarian and global health workers traveling to the DRC should follow the protocols of their organizations, ensure they have up-to-date emergency medical evacuation insurance, and register their travel with the State Department at step.state.gov.
- Do not assume you are protected by any existing Ebola vaccine — the available vaccines do not cover the Bundibugyo strain active in this outbreak.
- Follow updates from the WHO outbreak situation reports and ECDC rapid risk assessments for the most current official information.
Cost and Access: What Patients Should Know
Emergency medical evaluation for suspected Ebola exposure is available at designated biocontainment facilities in the United States. If you have returned from an affected region and develop symptoms, call your state or local health department first — they will coordinate the appropriate facility and testing protocols. Standard emergency rooms are not equipped for Ebola isolation, and calling ahead is critical.
Medical evacuation insurance is strongly recommended for anyone traveling to active outbreak zones. Organizations such as the U.S. Peace Corps, State Department contractors, and major NGOs typically provide coverage as part of their deployment packages, but independent travelers and researchers should confirm their own coverage before traveling.
What Happens Next
The most immediate policy decision to watch is whether the CDC and Department of Homeland Security extend the U.S. entry restrictions affecting travelers from DRC, Uganda, and South Sudan beyond the current July 21 expiration date. With the outbreak still growing, an extension appears likely — but no announcement had been confirmed as of July 17, 2026.
The WHO is expected to release an updated situation report this week. The ongoing clinical trial for MBP134 and remdesivir may produce preliminary safety and tolerability data within weeks, though efficacy results will take longer. MedicalDaily will update this report as new case data, restriction decisions, and treatment trial developments are confirmed.
The Bottom Line
The DRC Ebola outbreak is now the largest Bundibugyo Ebola event in recorded history and is still expanding. For most Americans, direct personal risk remains very low. For travelers to the region, aid workers, and global health professionals, this is an active and serious threat with no available vaccine and a rapidly expanding geographic spread. Monitor official updates closely, follow your organization's health and safety protocols, and seek immediate medical evaluation if you develop symptoms after travel to any affected area.
